PORTLAND, Ore.—A collaboration is underway between Nobilis Therapeutics, a biopharmaceutical company advancing CNS therapies based on noble gas mixtures, and The Linde Group to support Nobilis’ clinical research program regarding a drug/device combination to treat post-traumatic stress disorder (PTSD). While specific terms were not released, the agreement states that Nobilis and Linde will collaborate to develop options regarding future supply, manufacturing and commercialization for such a product in the U.S., Europe, Latin America and Asia Pacific markets. The partners will create a joint steering committee to collaborate on the ongoing research and development plans.

 

“Our preclinical and early efficacy studies in PTSD, panic disorder, [and] autism spectrum disorder suggest the general potential for such drug/device combination to be a promising therapeutic option for the treatment of patients with post-traumatic stress disorder, and potentially other psychiatric and neurodegenerative conditions,” said Dr. Vlad Bogin, founder and CEO of Nobilis Therapeutics.